Press Releases Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Delayed Nasdaq Other stock markets 20:55:48 10/05/2024 BST			5-day change	1st Jan Change
1.28 ^USD	-5.19%		-1.53%	+10.26%

04-16	Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	CI
03-18	Clearside Biomedical Names Victor Chong Chief Medical Officer	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update	05-09	AQ
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference	05-08	AQ
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024	04-30	AQ
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors	04-16	AQ
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	04-02	AQ
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	03-18	AQ
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	03-12	AQ
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024	02-29	AQ
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering	02-07	AQ
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	12-14	AQ
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update	11-13	AQ
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference	11-08	AQ
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting	11-07	AQ
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®	11-03	AQ
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting	11-02	AQ
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD	11-01	AQ
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023	31/10/23	AQ
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting	16/10/23	AQ
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China	04/10/23	AQ
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit	03/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Press Releases

Filters